Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 15Carcinoma, Hepatocellular 8Neoplasm Metastasis 3Rectal Neoplasms 2Melanoma 2Cholangiocarcinoma 2Advanced Colorectal Cancer 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1TAS 102 1Stomach Neoplasms 1Sarcoma 1Mesothelioma, Malignant 1Liver Neoplasms 1Gastrointestinal Stromal Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Fatigue 1Colorectal Cancer Metastatic 1Colorectal Cancer Liver Metastases 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Neoplasms 1Asian Colorectal Cancer Patients 1Advanced Colorectal Carcinoma 1Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy 1

Interventions

HMPL-013 2toripalimab 1tislelizumab 1sintilimab 1regorafenib 1raltitrexed 1pembrolizumab 1camrelizumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Colorectal Carcinoma × regorafenib × Clear all
NCT04771715 2021-02-25

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Peking Union Medical College Hospital

Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡